DZ Bank’s Stemline Therapeutics, Inc. STML Stock Holding History

DZ Bank’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-24,954	Closed	-$382K	–	1168
2018 Q1	$382K	Buy	+24,954	New	+$389K	﹤0.01%	835

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

DZ Bank's STML Position: Q2 2018 in Review

DZ Bank sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 24,954 shares — an estimated $382K sold.

DZ Bank first reported a position in STML in Q1 2018 and held it in 1 quarter. The position peaked at $382K in Q1 2018. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

DZ Bank reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 24,954 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $382K.
DZ Bank first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
DZ Bank's Stemline Therapeutics, Inc. position peaked at $382K in Q1 2018.
91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.